Vistagen Therapeutics (VTGN) Equity Average (2017 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Equity Average for 11 consecutive years, with $58.6 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 32.65% to $58.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.6 million through Dec 2025, down 32.65% year-over-year, with the annual reading at $92.3 million for FY2025, 46.14% up from the prior year.
- Equity Average hit $58.6 million in Q4 2025 for Vistagen Therapeutics, down from $61.6 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $118.8 million in Q1 2024 to a low of $9.5 million in Q2 2023.
- Historically, Equity Average has averaged $66.8 million across 5 years, with a median of $74.1 million in 2022.
- Biggest five-year swings in Equity Average: surged 12070.1% in 2021 and later plummeted 82.91% in 2023.
- Year by year, Equity Average stood at $80.3 million in 2021, then tumbled by 68.7% to $25.1 million in 2022, then soared by 216.09% to $79.5 million in 2023, then rose by 9.54% to $87.0 million in 2024, then plummeted by 32.65% to $58.6 million in 2025.
- Business Quant data shows Equity Average for VTGN at $58.6 million in Q4 2025, $61.6 million in Q3 2025, and $63.6 million in Q2 2025.